This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
RYBREVANT® (amivantamab-vmjw)
Medical Information
Safety Information for RYBREVANT – Infusion-Related Reactions
Last Updated: 09/05/2025
SUMMARY
A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:
- RYBREVANT®
(amivantamab-vmjw) – Safety Information for RYBREVANT – Infusion-Related Reactions - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below.
- RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
- LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.